Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Thompson (2011)
House legislation proposes early warning system for drug shortages.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 68 15
S. Moon (2013)
Respecting the right to access to medicines: Implications of the UN Guiding Principles on Business and Human Rights for the pharmaceutical industry.Health and human rights, 15 1
R. Barr, J. Robertson (2016)
Access to Cytotoxic Medicines by Children With Cancer: A Focus on Low and Middle Income CountriesPediatric Blood & Cancer, 63
P. Rosoff, K. Patel, A. Scates, Gene Rhea, P. Bush, J. Govert (2012)
Coping with critical drug shortages: an ethical approach for allocating scarce resources in hospitals.Archives of internal medicine, 172 19
G. Jones, H. Kantarjian (2015)
Health care in the United States--basic human right or entitlement?Annals of oncology : official journal of the European Society for Medical Oncology, 26 10
M. Metzger, A. Billett, M. Link (2012)
The impact of drug shortages on children with cancer--the example of mechlorethamine.The New England journal of medicine, 367 26
L. McGough, S. Reynolds, T. Quinn, J. Zenilman (2005)
Which patients first? Setting priorities for antiretroviral therapy where resources are limited.American journal of public health, 95 7
E. Kodish (2005)
Ethics and research with children : a case-based approach
G. Eom, P. Grootendorst, J. Duffin (2016)
The case for an essential medicines list for CanadaCanadian Medical Association Journal, 188
G. Persad, A. Wertheimer, E. Emanuel (2009)
Principles for allocation of scarce medical interventionsThe Lancet, 373
G. Bell, K. Caudle, M. Whirl‐Carrillo, R. Gordon, K. Hikino, C. Prows, A. Gaedigk, J. Agúndez, S. Sadhasivam, T. Klein, M. Schwab (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetronClinical Pharmacology & Therapeutics, 102
C. Rodríguez-Galindo, P. Friedrich, Patricia Alcasabas, F. Antillon, S. Banavali, L. Castillo, T. Israels, S. Jeha, Mhammed Harif, M. Sullivan, T. Quah, C. Patte, C. Pui, R. Barr, T. Gross (2015)
Toward the Cure of All Children With Cancer Through Collaborative Efforts: Pediatric Oncology As a Global Challenge.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 27
A. Denburg, B. Arora, R. Arora, Carmen Auste, P. Bagai, R. Barr, J. Challinor, T. Eden, Edith Grynzspancholc, R. Hoffman, Michael Link (2017)
Access to essential medicines for children with cancer: a joint SIOP-CCI position statement.The Lancet. Oncology, 18 1
C. Ventola (2011)
The drug shortage crisis in the United States: causes, impact, and management strategies.P & T : a peer-reviewed journal for formulary management, 36 11
N. Cherny, R. Sullivan, J. Torode, M. Saar, A. Eniu (2017)
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.Annals of oncology : official journal of the European Society for Medical Oncology, 28 11
D. Adams (1989)
Wartime bureaucracy and penicillin allocation: the Committee on Chemotherapeutic and Other Agents, 1942-44.Journal of the history of medicine and allied sciences, 44 2
Jill Beck, Laurie Smith, B. Gordon, J. Garrett (2015)
An ethical framework for responding to drug shortages in pediatric oncologyPediatric Blood & Cancer, 62
P. Rosoff (2012)
Unpredictable Drug Shortages: An Ethical Framework for Short-Term Rationing in HospitalsThe American Journal of Bioethics, 12
Elizabeth Salazar, M. Bernhardt, Yimei Li, R. Aplenc, P. Adamson (2015)
The impact of chemotherapy shortages on COG and local clinical trials: A report from the Children's Oncology GroupPediatric Blood & Cancer, 62
E. Fox, M. McLaughlin (2018)
ASHP guidelines on managing drug product shortagesAmerican Journal of Health-System Pharmacy, 75
A. McBride, L. Holle, Colleen Westendorf, Mary Sidebottom, N. Griffith, R. Muller, J. Hoffman (2013)
National survey on the effect of oncology drug shortages on cancer care.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 70 7
Bell (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron.Clin Pharmacol Ther, 102
N. Daniels, J. Sabin (2008)
Setting Limits Fairly: Learning to Share Resources for Health
M. Hudak, M. Helm, P. White (2017)
Principles of Child Health Care FinancingPediatrics, 140
S. Quilty, Lisa Harris, J. Kewley, Alison Jones, R. Pearce, Rosemary James, F. McGain (2011)
A Pandora's box: sustainable pharmaceutical supplyMedical Journal of Australia, 195
Zachary Frosch, A. Cronin, J. Gagne, Maxwell Teschke, S. Gray, G. Abel (2018)
Cancer drug shortages: Awareness and perspectives from a representative sample of the US populationCancer, 124
Malcolm Smith, S. Altekruse, P. Adamson, G. Reaman, N. Seibel (2014)
Declining childhood and adolescent cancer mortalityCancer, 120
M. Reidenberg (2007)
Essential Medicines for the Whole WorldClinical Pharmacology & Therapeutics, 82
Jill Beck, Baojiang Chen, B. Gordon (2017)
Physician approaches to drug shortages: Results of a national survey of pediatric hematologist/oncologistsWorld Journal of Clinical Oncology, 8
E. Fox, B. Sweet, Valerie Jensen (2014)
Drug shortages: a complex health care crisis.Mayo Clinic proceedings, 89 3
H. Parsons, Susanne Schmidt, A. Karnad, Yuanyuan Liang, M. Pugh, E. Fox (2016)
Association Between the Number of Suppliers for Critical Antineoplastics and Drug Shortages: Implications for Future Drug Shortages and Treatment.Journal of oncology practice, 12 3
(2012)
A shortage of everything except errors: harm associated with drug shortages.
Beck (2015)
An ethical framework for responding to drug shortages in pediatric oncology.Pediatr Blood Cancer, 62
A. Reece (2012)
What is wrong with Medicare?Medical Journal of Australia, 196
Mai Duong, R. Moles, B. Chaar, Timothy Chen (2015)
Essential Medicines in a High Income Country: Essential to Whom?PLoS ONE, 10
(2010)
Drug shortages: national survey reveals high level of frustration, low level of safety.
Valerie Jensen, L. Kimzey, M. Goldberger (2002)
FDA's role in responding to drug shortages.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 59 15
Y. Unguru, C. Fernandez, B. Bernhardt, S. Berg, K. Pyke-Grimm, Catherine Woodman, S. Joffe (2016)
An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer.Journal of the National Cancer Institute, 108 6
M. Decamp, S. Joffe, C. Fernandez, R. Faden, Y. Unguru (2014)
Chemotherapy Drug Shortages in Pediatric Oncology: A Consensus StatementPediatrics, 133
K. Gogineni, Katherine Shuman, E. Emanuel (2013)
Survey of oncologists about shortages of cancer drugs.The New England journal of medicine, 369 25
Pearce (2012)
A Pandora’s box: sustainable pharmaceutical supply.Med J Aust, 196
Diego Silva, J. Nie, K. Rossiter, S. Sahni, Ross Upshur (2016)
Contextualizing Ethics: Ventilators, H1N1 and Marginalized Populations
T. Millar, Shirley Wong, Donna Odierna, L. Bero (2011)
Applying the essential medicines concept to US preferred drug lists.American journal of public health, 101 8
In resource-rich countries, 5-year survival rates for children with cancer approach 85%. This impressive statistic is largely the result of integrating research with clinical care. At the core of this endeavor are multiagent combination chemotherapy and supportive care agents (CASCA). Most CASCAs belong to the class of sterile injectable drugs, which make up the backbone of many proven and life-saving pediatric oncology regimens. There are few if any alternative agents available to treat most life-threatening childhood cancers. In the United States, shortages of CASCAs are now commonplace. The consequences of drug shortages are far reaching. Beyond the economic costs, these shortages directly affect patients’ lives, and this is especially true for children with cancer. Drug shortages in general and shortages of CASCAs specifically result in increased medication errors, delayed administration of life-saving therapy, inferior outcomes, and patient deaths. One way to mitigate drug shortages is to adopt an essential medicines list and ensure that these medications remain in adequate supply at all times. We argue for creation of a CASCA-specific essential medicines list for childhood cancer and provide ethical and policy-based reasoning for this approach. We recognize that such a call has implications beyond pediatric cancer, in that children with other serious disease should have an equal claim to access to guaranteed evidence-based medicines. We provide these arguments as an example of what should be claimed for medical indications that are deemed essential to preserve life and function.
JAMA Pediatrics – American Medical Association
Published: May 4, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.